Patients with classic adrenal hyperplasia (CAH) may be able to reduce their glucocorticoid (GC) doses with crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, according to two studies recently published in The Journal of Clinical Endocrinology & Metabolism . Neurocrine Biosciences, Inc.
funded the studies, and the company is marketing crinecerfont as CRENESSITY®. The two papers — one focusing on adult care and the other pediatric care — present structured algorithms for reducing supraphysiologic glucocorticoid dosing, along with broader considerations for patient management in real-world practice.
Two teams of expert endocrinologists convened for these studies, drafting companion pieces with recommendations for the adult and pediatric patients. “New and emerging non-glucocorticoid therapies for [CAH] can reduce adrenocorticotropic hormone-mediated androgen production, allowing for [GC] dose reductions,” the authors write.
Endocrine News published a clinical update in Research Highlights on 02 Jun 2026.
The item focuses on Glucocorticoid Management in Patients with Classic Congenital Adrenal Hyperplasia with Crinecerfont.
Review the original article for the full source wording and details.